Orthocell (ASX:OCC) has released its Quarterly Report for the quarter ended 31 March 2026, highlighting continued revenue growth, strong commercial traction in the United States, and expanding global adoption of Remplir™.Key highlights:Orthocell delivered quarterly revenue of $3.2 million, driven primarily by increasing penetration of Remplir in existing markets and the commencement of material sales in the United States.
U.S. Remplir sales reached $300k in the March quarter, with $170k in Remplir sales recorded in March, providing early evidence of a potential revenue inflection point within the US$1.6 billion U.S. Remplir addressable market.
Year-to-date revenue reached $9.4 million, representing a 45% increase on the prior corresponding period and already exceeds full-year FY25 revenue of $9.2M
The Company maintains a strong cash position of $48 million, supporting ongoing commercial expansion.
With a now established and growing commercial distribution platform in the U.S., the Company anticipates a material uplift in U.S. revenue in the upcoming quarters.
Accelerating US commercialisationCommercialisation of Remplir in the United States continues to track ahead of expectations, supported by expanding distribution, hospital access, and surgeon adoption.
Distribution network now covers 16+ states, representing approximately 40% of the US population
32 Value Analysis Committee (VAC) approvals secured, providing access to more than 115 hospitals, with a further 57 applications in progress
49 surgeons have now used Remplir, with 115 units sold during the quarter
Growing validation in defence and real-world settingsReal-world utilisation of Remplir continues to build, including use in complex trauma environments.
Remplir has been used in 23 surgical procedures in Ukraine
Subsequent to the end of the quarter, approval has been secured for use across US Department of Defence hospital networks, with the first procedure already completed
These developments highlight the product’s suitability for high-demand surgical settings, including trauma and defence applications.Expanding global footprintOrthocell continues to progress its international commercial strategy:
Canada: Commercial rollout advancing, with initial sales expected shortly
UK/EU: Regulatory pathway remains on track, supported by distributor appointment and market development activities
Australia: Continued expansion of clinical applications, including nerve-sparing prostate cancer surgery
Orthocell CEO and Managing Director Paul Anderson said:“This quarter reflects continued strong progress in the commercialisation of Remplir, particularly in the United States, where we are seeing growing surgeon adoption and increasing revenue contribution. The consistency of our revenue performance and the growth in key commercial metrics, including hospital uptake, surgeon utilisation and distributor expansion, is particularly encouraging. Notably, the acceleration in U.S. revenue in March provides early evidence of a potential inflection point as these commercial efforts begin to scale” Click to read the ASX announcement.
